Howard Chertkow, MD, FRCPC, CAHS

Scientific Director

Canadian Consortium on Neurodegeneration in Aging



In 2005, Dr. Chertkow’s team published the Montreal Cognitive Assessment (MoCA), which has become an international standard for diagnosis of MCI. In 2006, he chaired the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, which brought together many of the country’s experts to formulate new guidelines for physicians.

Howard Chertkow is a cognitive neurologist, Professor of Neurology at McGill University in Montreal Canada, and he has been director of the Jewish General Hospital/ McGill University Memory Clinic for 20 years. His major areas of research interest include:

  1. Early diagnosis of Alzheimer’s Disease and prediction of deterioration in individuals with Mild Cognitive Impairment.
  2. The structure, organization, and function of the Semantic Memory component of long-term memory, and its deterioration in dementia.
  3. Localization of language and memory functions in the brain using functional imaging.
  4. Neuromodulation therapy for semantic impairment in Alzheimer Disease.

Dr. Chertkow is past president of the Consortium of Canadian Centres for Clinical Cognitive Research (C5R), the national Canadian organization of clinical research on Alzheimer’s Disease and he is currently the Scientific Director of the Canadian Consortium for Neurodegeneration and Aging(CCNA). In 2005 his team published the Montreal Cognitive Assessment (MoCA), which has become an international standard for diagnosis of MCI. In 2006 he chaired the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, which brought together many of the country’s experts to formulate new guidelines for physicians. These guidelines have been published nationally and internationally.

In 2008 he received the national Irma Parhad Award from C5R for contributions to excellence in AD research. In 2011 Dr. Chertkow was the only Canadian member of the National Institutes of Health team which revised the diagnostic criteria for AD (McKhann, Knopman, Chertkow et al, 2011. Alzheimer’s & Dementia. 7 (3), 263-269). Dr. Chertkow was recently elected to the Canadian Academy of Health Sciences.


Pascale Léon, PhD

Managing Director and Chief Operating Officer

Canadian Consortium on Neurodegeneration in Aging


 

Dr. Pascale Léon holds a graduate degree in Chemical Engineering from the Institut de chimie et physique industrielles (Lyon, France) and a PhD in Life and Health Sciences from the Université de Paris VI (France). She conducted her post-doctoral training at the Roche Institute of Molecular Biology in Nutley, New Jersey. She was then a Research Associate in Dr. Aled Edwards’ laboratory at the University of Toronto before directing a cancer research laboratory at the University Health Network (Toronto). In 2004, she became the Research Program Director and subsequently Executive Director of the Canadian Breast Cancer Research Alliance (CBCRA), a national partnership of public agencies and private foundations funding breast cancer research across Canada.

In that capacity she led the development of a National Breast Cancer Research Framework in 2009. More recently, she was at the Ontario Institute for Cancer Research (OICR) where she started in 2010 first as Director of Strategic Planning and then as Director of the Scientific Secretariat. She is the author of more than 30 scientific publications and has been invited to speak at several international cancer research conferences before pursuing a career in medical research management.


Victor Whitehead, B.Sc., M.S.W.

National Operations Manager

Canadian Consortium on Neurodegeneration in Aging


 

Victor Whitehead holds a Masters in Social Work and a Bachelors in Science with a major in Psychology, both from the University of Toronto. He has worked as a research assistant with Howard Chertkow for 17 years, participating in the design, implementation and analysis of over 30 projects in that time. He has also been involved in over 15 industry sponsored clinical trials, both as a site coordinator and as a test administrator.

He has been a member of the Society of Clinical Research Associates (SoCRA) since 2010 and is accredited as a Certified Clinical Research Professional. He is the co-author of 15 peer-reviewed articles. He has extensive knowledge in cognitive neuroscience, psychiatry, study design, and International Conference on Harmonization and Good Clinical Practice  guidelines. He was part of the team that developed the Montreal Cognitive Assessment, which is internationally recognized as a valuable addition to the assessment of cognition.


Terrence Li, BSc, MBA

Research Financial Planner

Canadian Consortium on Neurodegeneration in Aging



Terrence Li holds a Bachelor of Science degree in Bio-organic Chemistry from McGill University, and a Master of Business Administration (MBA) degree from Vancouver Island University. He brings a wealth of experience to the CCNA. He has worked as a Research Assistant in Dr. Theo van de Ven’s pulp and paper laboratory at McGill University. While completing his MBA, he was an intern at the headquarters of the United Nations in New York.

After obtaining his MBA and getting his mutual fund license, Terrence pursued more analytical roles. He was an Equity Day Trader, which then led him into the field of Fund Accounting. He was employed at a custodian bank and then worked for the Government of Canada at Canada Revenue Agency.